Explore the latest in cancer biomarkers, including advances in identifying precision markers for selecting treatment and predicting outcomes.
This economic evaluation modeled the cost-effectiveness of 5 neoadjuvant-adjuvant treatment strategies for women with ERBB2-positive breast cancer.
This systematic review and meta-analysis uses data from studies retrieved from a Cochrane Library, ScienceDirect, PubMed, and Embase search to investigate the association of circulating tumor DNA with disease-free survival in patients with breast cancer.
This case series study examines the prevalence of clonal hematopoiesis and its potential interference in prostate cancer cell-free DNA testing.
This phase 3 randomized clinical trial assesses the efficacy of a clinician-driven treatment choice vs a circulating tumor cell count–driven choice for first-line treatment among women with hormone receptor–positive, ERBB2-negative metastatic breast cancer.
This cross-sectional study assesses whether the rate of positive BRCA test results changed between 2008 and 2018 among older women in the United States.
This decision analysis estimates the lifetime incremental incidence of hereditary breast and ovarian cancer and the quality-adjusted life-years, costs, and cost-effectiveness of hereditary breast and ovarian cancer genomic screening in an unselected population vs family history–based testing.
This cohort study examines tumor mutational burden in patients with uncommon cancers not receiving immunotherapy as a biomarker associated with overall survival.
This case series characterizes the antitumor activity of platinum-based therapies in men with castration-resistant prostate cancer with or without DNA repair gene alterations.
This prognostic study examines the use of endothelial cell phosphorylated-focal adhesion kinase as a biomarker for chemotherapy sensitivity in women with breast cancer.
This systematic review and network meta-analysis clarifies which first-line treatment is associated with the best tumor response among patients with extensive-stage small cell lung cancer (SCLC).
This cohort study describes the incidence rates of 4 breast cancer molecular subtypes stratified by race/ethnicity among women in the US.
This systematic review and meta-analysis evaluates 9 randomized clinical trials to assess whether adding cyclin-dependent kinases 4 and 6 inhibitors to endocrine therapy is associated with increased overall survival or with adverse events vs endocrine therapy alone among patients with hormone receptor (HR)–positive, ERBB2-negative metastatic breast cancer.
This meta-analysis examines the association of methodologic differences in study design with observed performance of molecular assays for indeterminate thyroid nodules.
This phase 1 trial assesses the safety, antitumor activity, and pharmacokinetics of toripalimab in patients with advanced non–small cell lung cancer (NSCLC) and evaluates the utility of JS311, a novel programmed death cell ligand 1 immunohistochemistry assay.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: